期刊文献+

抗凝药物在妊娠期静脉血栓栓塞疾病中的应用 被引量:5

Application of anticoagulation medications in venous thromboembolism during pregnancy
下载PDF
导出
摘要 妊娠相关静脉血栓栓塞疾病是导致孕产妇死亡的主要原因之一,且近年来发病率有上升趋势。在适宜的时机合理使用抗凝药物对于妊娠相关静脉血栓栓塞疾病的防治、改善母婴结局尤为重要。本文介绍了妊娠期静脉血栓栓塞疾病高危因素的评估方法及妊娠期抗凝药物的使用原则,以期能够为相关问题的临床用药提供借鉴和参考。 Venous thromboembolism(VTE)is one of the leading causes of maternal mortality,and the incidence is increasing in recent years.Reasonable anticoagulation therapy at proper time is important to the prevention and treatment of pregnancy-related venous thromboembolism as well as the improvement in maternal and infant outcome.The purpose of this document is to provide information regarding the risk factors,therapy and prevention of VTE in pregnancy.
作者 黄桦 张峻 HUANG Hua;ZHANG Jun(First Affiliated Hospital of Kunming Medical University,Kunming 650032,China)
出处 《实用药物与临床》 CAS 2019年第12期1233-1237,共5页 Practical Pharmacy and Clinical Remedies
基金 国家自然科学基金(81560252) 云南省科技厅-昆明医科大学应用基础研究联合专项重点项目[2018FE001(-167)] 云南省卫生科技计划项目(2017NS070) 云南省高层次卫生计生技术人才培养专项经费资助(L-201614、H-2017051)
关键词 抗凝药物 妊娠期 静脉血栓栓塞疾病 Anticoagulation medications Pregnancy Venous thromboembolism
  • 相关文献

参考文献2

二级参考文献22

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2FRANCO R F,REITSMA P H.Genetic risk factors ofvenous thrombosis[J].Hum Genet,2001,109(4):369-384.
  • 3BARCZYK A,PIERZCHALA W.Risk factors of venous thromboembolism[J].Wiad Lek,2001,54(5-6):311-324.
  • 4LEVINE A B,TEPPA J,McGOUGH B,et al.Evaluation of the prethrombotic stae in pregnancy and in women using oral contraceptives[J].Contraception,1997,55(1):53.
  • 5GRUBER U F,DUCKERT F,FRIDRICH R,et al.Prevention of postoperative thromboembolism by dextran 40,low doses of heparin,orxantinolnicotinate[J].Lancet,1997,1:210.
  • 6Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 7Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 8Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 9Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 10Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.

共引文献631

同被引文献33

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部